Clinical characteristics and outcome of vasculitides

Similar documents
Atlas of the Vasculitic Syndromes

Vasculitis. Edward Dwyer, M.D. Division of Rheumatology. Vasculitis

Dr Rodney Itaki Lecturer Anatomical Pathology Discipline. University of Papua New Guinea School of Medicine & Health Sciences Division of Pathology

PAEDIATRIC VASCULITIS

A prospective study of vasculitis patients collected in a five year period: evaluation of the Chapel Hill nomenclature

Diagnostic Procedures for Vasculitis

Mohammad Reza Shakibi M.D Kerman university of medical sciences (KMU) Shafa Hospital, Rheumatology ward

VASCULITIS. Case Presentation. Case Presentation

Vasculitis of the peripheral nervous system

Vasculitis (Polyarteritis Nodosa, Microscopic Polyangiitis, Wegener s Granulomatosis, Henoch- Schönlein Purpura)

Vasculitis Update. A selective review of what s new. Dr Jonathan Akikusa MBBS FRACP

Vasculitis and Vasculitides. OMONDI OYOO Physician/Rheumatologist; Senior Lecturer, Department of Medicine University of Nairobi

Case Presentation VASCULITIS. Case Presentation. Case Presentation. Vasculitis

ANCA associated vasculitis in China

AN OVERVIEW OF ANCA-ASSOCIATED VASCULITIS

RARE JUVENILE PRIMARY SYSTEMIC VASCULITIS

Index. Note: Page numbers of article titles are in boldface type.

CENTRAL NERVOUS SYSTEM VASCULITIS

The role of pathology in the diagnosis of systemic vasculitis

Scleritis LEN V KOH OD

Case Rep Nephrol Urol 2013;3: DOI: / Published online: January 27, 2013

Guideline on the clinical management of Henoch Schonlein Purpura (HSP)

V asculitis is an inflammatory process of blood vessels,

EDITORIAL. Issue Seventeen, October Editorial Team. Issue Seventeen. Info link

Small Vessel Vasculitis

Update on nomenclature and classification of vasculitis

Vasculitides in Surgical Neuropathology Practice

VASCULITIS AND VASCULOPATHY

2/23/18. Disclosures. Rheumatic Diseases of Childhood. Making Room for Rheumatology. I have nothing to disclose. James J.

Vasculitis local: systemic

Vasculitis Prof. Dr. med. Katharina Glatz Pathologie

GIANT CELL ARTERITIS. Page 1 of 6 Reproduction of this material requires written permission of the Vasculitis Foundation. Copyright 2018.

GRANULOMATOSIS WITH POLYANGIITIS

KAWASAKI DISEASE. What is Kawasaki disease? Causes

Classification and classification criteria for vasculitis: achievements, limitations and prospects

VASCULITIC SYNDROMES. Howard L. Feinberg, D.O., F.A.C.O.I., F.A.C.R. OPSC 2018

Autoimmune Disease. Autoimmunity. Epidemiology. ACR Criteria for Diagnosis. Signs and Symptoms. Autoreactivity: Reactivity to self antigens:

Autoimmunity. Autoimmune Disease

Vasculitis local: systemic

Arthritis & Rheumatism DOI /art.00000

Management of Acute Vasculitis. CMT teaching 3 rd June 2015 Caroline Wroe

SHO Teaching. Dr. Amir Bhanji Consultant Nephrologist, Q.A hospital, Portsmouth

Curricular Components for Rheumatology EPA

Stable Incidence of Systemic Vasculitides in Schleswig-Holstein, Germany Karen Herlyn, Bernhard Hellmich, Wolfgang L. Gross, Eva Reinhold-Keller

Disease flares, damage accrual and survival in ANCA-associated vasculitis in Western Australia

A number of factors point to the likelihood of a person with RA developing RV:

Renal outcome of kidney-transplantation in Korean recipients with ANCA-associated vasculitis

FAQ Identifying and enrolling participants

December 6, 2010 Asthma and Rheumatic Disorders and Vasculitis

SMALL TO MEDIUM VASCULITIS: RENAL ASPECT RATANA CHAWANASUNTORAPOJ UPDATE IN INTERNAL MEDICINE 2018

Annual Rheumatology & Therapeutics Review for Organizations & Societies

ANCA Associated vasculitis presenting as bilateral pleural effusion: A rare case report

A. Smržová. III. Interní klinika FN Olomouc nefrologická, revmatologická a endokrinologická

AKI Case study -Vasculitis. Sarah Mackie Renal Practice Development Nurse King s College Hospital - London

EUVAS update June 5 th Marinka Twilt

A Study of Atherosclerosis in Systemic Vasculitis

The European and French networks. Christian Pagnoux, MD, MSc, MPH Mount Sinai Hospital, Toronto, Canada Cochin Hospital, Paris, France

Small Vessel Vasculitis

anti-neutrophil cytoplasmic antibody, myeloperoxidase, microscopic polyangiitis, cyclophosphamide, corticosteroid

ARTHRITIS FOUNDATION VASCULITIS

Kelley's Textbook of Rheumatology. 2 Volume Set. Text with Internet Access Code for Premium Consult Edition

Managing Acute Medical Problems, Birmingham Vasculitis. David Jayne. University of Cambridge

Diagnostic Tests in Rheumatic Disease: What s Old, What s New & What s Useful? COPYRIGHT

TAKAYASU S ARTERITIS. Second-stage symptoms include:

ST - segment Elevation Myocardial Infarction complicating an atypical Kawasaki disease

Cerebrovascular Disease

Rituximab treatment for ANCA-associated vasculitis in childhood

Overview. = inflammation of vessel wall. Symptoms and signs depend on the tissue of which the vessels are affected

Presenting Features in Pakistani Patients Suffering from the Antineutrophil Cytoplasmic Antibody - Classical Subtype (c- ANCA) Associated Vasculitis

Reporting Autoimmune Diseases in Hematopoietic Stem Cell Transplantation

Microscopic polyangiitis complicated with ileal involvement detected by double-balloon endoscopy: a case report

Done by: Shatha Khtoum

RaDaR Inclusion and Exclusion Criteria. Diagnosis Inclusion Criteria Exclusion Criteria. Alport Syndrome definite or probable

DIABETES MELLITUS. Kidney in systemic diseases. Slower the progression: Pathology: Patients with diabetes mellitus are prone to other renal diseases:

DISEASE ASSESSMENT IN SYSTEMIC VASCULITIS R A Luqmani

Key words Microscopic polyangiitis, Wegener s granulomatosis, Henoch-Schönlein purpura, ANCA-associated vasculitis.

Rate of infections in severe necrotising vasculitis patients treated with cyclophosphamide induction therapy: a meta-analysis

Henoch-Schonlein Purpura Guidelines

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

The Vasculitis Syndromes

Research Article Evaluation of 10-Year Experience of Wegener s Granulomatosis in Iranian Children

Vasculitis in primary connective tissue diseases

Rheumatology. Modern management of primary systemic vasculitis CME: CLINICAL PRACTICE AND ITS BASIS

The systemic vasculitides were traditionally classified. Treatment of ANCA-associated Systemic Vasculitis. H. Michael Belmont, M.D.

Original Article. Abstract

Does this patient have vasculitis?

Glucocorticoids and Relapse and Infection Rates in Anti-Neutrophil Cytoplasmic Antibody Disease

Review Articles. Childhood Vasculitis - An Update MOHAMMAD IMNUL ISLAM 1, MANIK KUMAR TALUKDAR 1, SHAHANA AKHTER RAHMAN 2

VCRC-OMERACT ANCA-Vasculitis Outcome Measure Initiative Comparative Outcome Measure Exercise-Training Cases

Current Classifications

Cardiovascular Pathology

Sung Soo Ahn 1, Seung Min Jung 1, Jason Jungsik Song 1,2, Yong-Beom Park 1,2 and Sang-Won Lee 1,2*

SCOTTISH REAL BIOPSY REGISTRY: SURVEY OF NATIVE KIDNEY BIOPSY IN SCOTLAND 2015

Vascularites rénales associées aux ANCA

29 Glomerular disease: an overview

Neuropathology lecture series. III. Neuropathology of Cerebrovascular Disease. Physiology of cerebral blood flow

Case Report Testicular Vasculitis: A Sonographic and Pathologic Diagnosis

Clinical Commissioning Policy: Rituximab For ANCA Vasculitis. December Reference : NHSCB/ A3C/1a

Cutaneous manifestations and systemic correlation in patients with lupus erythematosus and its subsets: a study of 40 cases

Year In Review: VasculitisPers. Disclosures. Learning Objectives. none 4/16/2018. Describe new medications for the treatment of vasculitis

Transcription:

GENERAL SECTION ORIGINAL ARTICLE Clinical characteristics and outcome of vasculitides Buddhi Prasad Paudyal, 1 Madhu Gyawalee 2 ISSN: 2091-2749 (Print) 2091-2757 (Online) Correspondence Dr. Buddhi Prasad Paudyal Department of Medicine Patan Academy of Health Sciences, Lalitpur, Nepal Email: buddhipaudyal@pahs.edu.np Peer Reviewed By Dr. Nabees Man Singh Pradhan Patan Academy of Health Sciences Peer Reviewed By Dr. Jay N Shah Patan Academy of Health Sciences 1 Associate Professor, Department of Medicine, 2 Lecturer, Department of Dermatology, Patan Academy of Health Sciences, Lalitpur, Nepal ABSTRACT Introductions: Vasculitides can cause significant morbidity and mortality if not treated on time. There is lack of data locally. This study aims to define the pattern, clinical characteristics, and outcome of vasculitides. Methods: This was a cross sectional study between January 2011 and December 2015 at Patan Hospital, Patan Academy of Health Sciences, Lalitpur, Nepal. The medical records of patients diagnosed with vasculitides in adults rheumatology service of the hospital were reviewed. Results: Ninety six patients were diagnosed with vasculitides during the study period. The mean age was 42.2 years. Sixty nine (71.8%) patient had small vessel, 20 (20.8%) large vessel and five (5.2%) had variable vessel vasculitides. Seventy five patients (78.1%) had primary and 21 (21.8%) secondary vasculitides. Cutaneous leucocytoclasticangitis was seen in 27 (28.1%), Takayasu arteritis in 17 (17.7), Henoch-Schonlein purpura in 11 (11.4%) and Rheumatoid arthritis associated vasculitis in nine patients. Purpura was present in all 96 (100%). The overall mortality was 9 (9.3%). Conclusions: Primary vasculitides were more common than secondary forms. Small vessel vasculitis was the most common. Cutaneous symptoms were predominant features. The mortality was attributed to active disease, sepsis, and complications of the primary disease. Keywords: Clinical characteristics, outcome, vasculitis, Patan Hospital, Nepal 3

INTRODUCTIONS Vasculitides are a heterogeneous group of diseases defined by the presence of inflammatory infiltrates in the blood vessel walls. Spread over several entities, these are rare but important clinical conditions. Timely identification and treatment can significantly decrease the associated morbidity and mortality. 1 Epidemiological data on vasculitides are mostly from Western countries. In Europe, the annual incidence of primary systemic vasculitides is approximately 20 per million population. 2 Studies have showed that vasculitides are common in elderly; however, the prevalence differs in different populations. In Western Nepal, only one case of vasculitis was observed in a series of 365 rheumatic cases. 3 Except few case reports and small series 4,5 on vasculitis, there is lack of data on clinical presentation and outcome locally. This study aims to assess clinical characteristics and outcome of vasculitic diseases from a tertiary care teaching hospital in Kathmandu, Nepal. METHODS This was a cross sectional study conducted at Patan Hospital, Patan Academy of Health Sciences (PAHS), Lalitpur, Kathmandu, Nepal. The medical records of patients diagnosed with vasculitides in the adult rheumatology service (medical outpatient and different wards) of Patan Hospital from 1 st January 2011 to 31 st December 2015 were reviewed. Patient s demographic data and clinical information on type and subtype of vasculitides, presentation, laboratory, imaging and biopsy, treatment, and outcome until the last follow up of few days to a maximum of 4 years were recorded. Investigations and imaging studies included were: rheumatoid factor (RF), antinuclear antibody (ANA), anti-double stranded deoxyribonucleic acid (anti-dsdna) antibodies, antineutrophil cytoplasmic antibodies (c-anca & p-anca), serological tests for hepatitis B, hepatitis C, human immunodeficiency virus (HIV), and angiogram of the aorta/affected blood vessels in selected patients. Children below 14 years of age were excluded. For primary vasculitides, the diagnosis was based on American College of Rheumatology (ACR) 1990 vasculitis classification criteria 6 and Chapel Hill Consensus Conference 1992 vasculitis nomenclature system. 7 For secondary vasculitides, diagnosis was based on clinical manifestations supported by appropriate investigations. Patients were treated according to the standard treatment protocol for that particular type of vasculitis 8,9 and followed up every 3 to 6 months. Outcome at last follow up was recorded. A broad outcome measure was used, which is also used for childhood systemic lupus erythematosus. 10 The outcome was grouped as remission on treatment, active disease despite treatment, lost to follow up, and death. The death at home or other health facility was confirmed by interrogating with the family members or relatives. Ethical approval was taken from Institutional Review Committee of PAHS. SPSS was used for descriptive analysis. RESULTS There were 96 patients diagnosed with vasculitides during the study period. Mean age was 42.2 years (range 18-78). Female to male ratio was 2:1. Sixty-nine (71.8%) patients had small vessel, 20 (20.8%) large vessel, five (5.2%) variable vessels and two (2%) had medium vessel involvement. Primary vasculitides was present in 75 (78.1%) and secondary in 21 (21.9%), (Table 1). Clinical manifestations of vsaculitis presented varyingly, Table 2. The outcome was good in 37 (38.5%) cases, (Table 3). Mortalities in primary vasculitides were one (1%) case each of Takayasu arteritis and Wegener s granulomatosis; and one (1%) case each of polyarteritis nodosa and microscopic polyangiitis. Among secondary vasculitides, mortalities were all two (2%) cases of malignancy associated and one (1%) case of lupus associated mesenteric vasculitis. 4

Table 1. Frequency distribution of vasculitic disorders at Patan Hospital Type Male Female Mean age y Large vessel vasculitis (n= 20) Takayasu arteritis (17) 2 15 30.71 Gaint cell arteritis (3) 1 2 71.33 Medium vessel vasculitis (n= 2) Polyarteritis nodosa (2) 1 1 45 Wegener s granulomatosis or granulomatosis with polyangiitis (7) 3 4 55.29 Churg-Strauss syndrome (2) 1 1 41 Small vessel vasculitis (n=69) Primary (48) Microscopic polyangiitis (1) 1 0 57 Henoch-Schonlein purpura or IgA vasculitis (11) 6 5 32.45 Cutaneous leucocytoclastic angiitis (27) 9 18 43.3 Rheumatoid arthritis associated (9) 2 7 58.11 Secondary Systemic lupus erythematosus associated (6) 0 6 27.83 (21) Malignancy associated (2) 2 0 66.5 Drug associated (4) 3 1 43.75 Variable vessel vasculitis (n=5) Behcet s disease (5) 2 3 35 5

Table 2. Common manifestations of some forms of vasculitides Diagnostic category (n) Presenting features Number (%) Takayasu arteritis (17) Loss of pulses 16(94%) Arthritis/arthralgia/myalgia 16 (94%) Fever 8 (47%) Hypertension 8 (47%) Headache 4 (24%) Stroke 2 (12%) Wegener s granulomatosis (7) Eye inflammation* 6 (86%) Arthritis/arthralgia/myalgia 6 (86%) Nasal/Paranasal symptoms 5 (71%) Fever 5 (71%) Renal manifestations 5 (71%) Pulmonary features 5 (71%) Neuropathy 5 (71%) Purpura 2 (29%) Henoch-Schonlein purpura (11) Purpura 11 (100%) Arthritis/arthralgia/myalgia 11 (100%) Abd. Pain/GI bleeding 5 (45%) Renal manifestations 4 (36%) Cutaneous leucocytoclastic angiitis (27) Purpura 27 (100%) Arthritis/arthralgia/myalgia 10 (37%) Note: *Eye inflammation: scleritis, keratitis, proptosis, scleromalacia; Nasal/paranasal symptoms: sinusitis, epistaxis, nasal septum perforation, nasal crusts; Renal symptoms: haematuria, proteinuria, elevated creatinine; Pulmonary symptoms: haemoptysis, infiltrates/cavities/nodules on x-ray or CT scan 6

Table 3. Clinical outcome of vasculitides (n=96) Outcome Number (%) Disease remission while on 37 (39%) treatment Active disease despite treatment 15 (16%) Lost to follow up 35 (36%) Death 9 (9%) DISCUSSIONS In this study mean age of the patients with vasculitis was 42 years. Vasculitis, being a broad constellation of disorders, is a disease of all age groups. Different forms of vasculitides have different age predilection. Primary vasculitides like Takayasu arteritis and Henoch- Schonlein purpura are more common in young age group whereas most of the other forms of primary systemic vasculitides, particularly Giant cell arteritis are more common with advancing age. 11 The relative lower mean age in this series could be due to predominance of Takayasu arteritis, cutaneous leucocytoclastic angiitis and Henoch-Schonlein purpura which are all more common in young age group and at the same time, relative rarity of other forms of primary vasculitides which are more often seen in elderly. There was female predominance (male:female ratio of 1:2), and more so for diseases like Takayasu arteritis, cutaneous leucocytoclastic angiitis, and secondary vasculitides associated with autoimmune diseases like RA and SLE. Similar female predominance in different types of vasculitides is reported from India. 12,13 In this study, primary vasculitis was more common than secondary vasculitis in general, 78% versus 22% respectively in both sexes. The most common form of vasculitis in our study was cutaneous leucocytoclastic angiitis, followed by Takayasu arteritis, Henoch- Schonlein purpura, and RA associated secondary vasculitis. Cutaneous vasculitis was also a predominant form of vasculitis in studies from Western India 13 and Denmark. 14 The relative excess of Takayasu arteritis over other primary vasculitides may be due to the fact that this disease is more prevalent in Asian countries. 15 Henoch-Schonlein purpura is predominantly a disease of childhood; however, several studies have observed that this disease also comprises significant proportion of vasculitis in adult population. 6,12 Other forms of systemic vasculitides, particularly Giant cell arteritis, Polyarteritis nodosa, Churg-Strauss syndrome, and Microscopic polyangiitis were less common as in other series. 12,16 Behcet s disease, which can affect veins in preference to arteries and can affect all sizes of blood vessels, was observed in five patients (5.2%) in our study. The relative rarity of Behcet s disease in our series as compared to Indian 12 and Iranian studies 16 could either be due to rarity of this disease in our population or due to lack of referral to rheumatology service. Takayasu arteritis often causes granulomatous inflammation of the aorta and/or its major branches and more often begins before the age of 50 years. 17 The most common way of presentation in our population was muscle and joint pain and lack of pulses on physical examination, in 94% of cases. Approximately half (47%) presented with hypertension, whereas two cases developed stroke as a complication of the disease. Takayasu arteritis is the commonest cause of renovascular hypertension in India, 18 so early identification and treatment to optimal level is essential to avoid complications of hypertension like stroke and myocardial ischaemia. Many cases of Wegener s granulomatosis in our series had diffuse disease and presented with multisystem involvement including kidneys. One patient underwent renal transplantation for end-stage kidney disease. Relapse of disease was seen in three cases; one patient had multiple relapses. She had bilateral parotid enlargement as part of relapse before she died of severe sepsis. Though ours was a small series and not directly comparable with data from larger series, the relapse in treated Wegener s granulomatosis is as high as 57%. 19 7

Both Henoch-Schonlein purpura and cutaneous leucocytoclastic angiitis presented with purpuric rashes in 100% of cases. In Henoch- Schonlein purpura, renal involvement in the form of haematuria and proteinuria was observed in almost half of the patients whereas gastrointestinal involvement was seen in 36% of cases. Several other studies have also highlighted that Henoch-Schonlein purpura is more severe in adults particularly with renal involvement. 20 As we were dealing with several different types of vasculitides, we used a broad outcome measures which has also been used for childhood systemic lupus erythematosus. 10 More than one third of our patients lost to follow up. It appeared that many patients with milder forms of the disease particularly cutaneous vasculitides lost to follow up. Nine patients died in this series; two each from Wegener s granulomatosis, Takayasu arteritis and malignancy associated secondary vasculitis; and one each from Polyarteritis nodosa, SLE and Microscopic polyangiitis. In Wegener s granulomatosis, one patient died of active disease whereas another succumbed to severe sepsis. In Takayasu arteritis, one patient died due to acute left ventricular failure due to uncontrolled hypertension, whereas the cause of death was not clear in the second who died at home. In malignancy associated vasculitis, the cause of death was terminal cancer. In all other cases, the death was due to active vasculitis. As different forms of vasculitides present, with different manifestations, to different subspecialists, only patients seen in rheumatology service were included in this study. Thus, some form of vasculitides like renal-limited vasculitis and primary central nervous system vasculitis could have been missed, whereas others like Behcet s disease could have been under represented. Similarly, as this study was conducted in patients older than 14 years of age, vasculitis presenting exclusively in childhood, particularly Kawasaki disease was not observed in this study. Through this study, we have tried to provide a bird s eye view of vasculitis scenario from a hospital in central Nepal. Being a single centre report of retrospective design and with small sample size, this study may not reflect the true picture of the extent and problem of vasculitides in Nepal. Nevertheless, we believe that this study will open up avenues for future research and on that ground more comprehensive vasculitis database and prospective studies can be planned in the future. CONCLUSIONS Primary vasculitides were more common than secondary forms of vasculitides in general and in both the sexes. Small vessel vasculitis was the most commonly observed form of vasculitides; cutaneous leucocytoclastic angiitis, Henoch-Schonlein purpura, and autoimmune disease associated secondary vasculitides were more frequent presentations. Purpura was the most frequent presentation in cutaneous leucocytoclastic angiitis and Henoch-Schonlein purpura whereas other forms of vasculitides presented with multisystem involvement. The overall mortality rate of 9% was attributed to active disease, sepsis, and complications of the primary disease. ACKNOWLEDGEMENTS We would like to thank Mr. Anil Sharma, Librarian, Patan Academy of Health Sciences, for his help during manuscript preparation. REFERENCES 1. Watts RA, Scott DG. Recent developments in the classification and assessment of vasculitis. Best Pract Res Clin Rheumatol. 2009;23:429-43. 2. Watts R, Carruthers D, Scotts D. Epidemiology of systemic vasculitis: changing incidence or definition? Semin Arth Rheum. 1995;25;28-34. 8

3. Das RN, Paudel R. Spectrum of rheumatological disorders: an experience of 337 cases in a tertiary care hospital in Pokhara valley, Nepal. APLAR Journal of Rheumatology. 2006;9:248-56. 4. Paudyal B, Gyawalee M, Manandhar A, Sigdel K. Behcet s disease: an account of three cases. J Nepal Health Res Counc. 2012:10(22):250-53. 5. Paudyal BP, Pantha S, Ranjitkar N, Manandhar A, Arjyal A. A diagnosis missed for several years- Wegener s granulomatosis. Kathmandu Univ Med J. 2011;35(3):218-21. 6. Bloch DA, Michel BA, Hunder GG, McShane DJ, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Patients and methods. Arthritis Rheum. 1990;33:1068-73. 7. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994;37:187-92. 8. Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W et al for the European Vasculitis Study Group. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009;68:310 17. 9. Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W et al for the European Vasculitis Study Group. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2009;68:318-23. 10. Agarwal I, Kumar TS, Ranjini K, Kirubakaran C, Danda D. Clinical Features and Outcome of Systemic Lupus Erythematosus. Indian Pediatr. 2009;46(17):711-15. 11. Watts RA. Epidemiology of Vasculitis in India- What is known? J Indian Rheumatol Assoc. 2005;13: 8-15. 12. Joshi VR, Mittal G. Vasculitis- Indian Perspective. J Assoc Physicians India. 2006;54Suppl:12-4. 13. Samant R, Vaidya SS, Nadkar MY, Borges NE. Spectrum of clinical features of vasculitides in a referral hospital from Western India. J Indian Rheumat Assoc.1997;5:6-14. 14. Sorensen SF, Slot O, Tvede N, Petersen J. A prospective study of vasculitis patients collected in a five year period: evaluation of the Chapel Hill nomenclature. Ann Rheum Dis. 2000;59:478-82. 15. Moriwaki R, Noda M, Yajima M, Sharma BK, Numano F. Clinical Manifestations of Takayasu Arteritis in India and Japan- New Classification of Angiographic Findings. Angiology The Journal of Vascular Diseases. 1997;48(5):369-79. 16. Jokar MH, Mirfeizi Z. Epidemiology of Vasculitides in Khorasan Province, Iran. Iran J Med Sci. 2015;40(4):362-66. 17. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65:1-11. 18. Sharma BK, Sagar S, Singh AP, Suri S. Takayasu Arteritis in India. Heart Vessels. 1992 (Suppl);7:37-43. 19. Chen M, Yu F, Zhao MH. Relapses in patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: likely to begin with the same organ as initial onset. J Rheumatol. 2008;35(3):448-50. 20. Blanco R, Martinez-Taboada P, Rodriguez- Valverde V, Garcia-Fuentes M, Gonzalez- Gay MA. Henoch-Schonleinpurpura in adulthood and childhood: two different expressions of the same syndrome. Arthritis Rheum. 1997:40:859. 9